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Abstract: Superparamagnetic iron oxide nanoparticles 
(SPIONs) have been identified as a promising material for 
biomedical applications. These include as contrast agents 
for medical imaging, drug delivery and/or cancer cell 
treatment. The nanotoxicological profile of SPIONs has 
been investigated in different studies and the distribution 
of SPIONs in the human body has not been fully charac-
terized. The aim of this study was to develop a physiologi-
cally-based pharmacokinetic (PBPK) model to predict the 
pharmacokinetics of SPIONs. The distribution and accu-
mulation of SPIONs in organs were simulated taking into 
consideration their penetration through capillary walls 
and their active uptake by specialized macrophages in the 
liver, spleen and lungs. To estimate the kinetics of SPION 
uptake, a novel experimental approach using primary 
macrophages was developed. The murine PBPK model 
was validated against in vivo pharmacokinetic data, and 
accurately described accumulation in liver, spleen and 
lungs. After validation of the murine model, a similar 
PBPK approach was developed to simulate the distribu-
tion of SPIONs in humans. These data demonstrate the 
utility of PBPK modeling for estimating biodistribution 
of inorganic nanoparticles and represents an initial plat-
form to provide computational prediction of nanoparticle 
pharmacokinetics.
Keywords: accumulation; biodistribution; nanoparticles; 
physiologically based pharmacokinetic model; prediction.
Introduction
Superparamagnetic iron oxide nanoparticles (SPIONs) 
are a nanotechnology with favorable characteristics for 
biological and medical applications such as magnetic 
resonance imaging (MRI) (1, 2), drug delivery (2), cellular 
therapy, cell labeling (3, 4), tissue repair (5) and cancer 
treatment through hyperthermia (6). However, the bio-
medical applications of SPIONs may be limited by their 
low biocompatibility and toxicity. The nanotoxicologi-
cal profile of SPIONs has been investigated in different 
studies, highlighting the generation of oxidative stress, 
cell proliferation inhibition, mitochondrial damage 
and endoplasmic reticulum stress (7–10). Knowledge of 
the in  vivo biodistribution of SPIONs is essential for a 
robust assessment of all medical applications. Although 
the toxicology of SPIONs has been investigated, there 
is a current paucity of data relating to in vivo pharma-
cokinetics. Thorough understanding of the mechanisms 
regulating nanoparticles (NPs) pharmacokinetics is 
essential to design effective and safe NPs for biomedical 
applications.
Physiologically based pharmacokinetic (PBPK) 
modeling combines mathematical equations to describe 
the anatomical, physiological and molecular pro-
cesses regulating pharmacokinetics, with in vitro data 
to simulate and predict the absorption, distribution, 
metabolism and elimination (ADME) of conventional 
and nano-enabled medicines (11, 12). Several processes 
influence the distribution of NPs in the human body 
and the ADME of NPs can substantially differ from 
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traditional formulations, complicating the development 
of PBPK models. Macrophages are specialized cells that 
can phagocytose nanomaterials and represent an essen-
tial component of the reticuloendothelial (RE) system in 
organs such as the liver and spleen (11, 13, 14). Moreover, 
the “enhanced permeability and retention” (EPR) effect 
increased uptake of NPs in tumors and inflamed sites, 
and represents a passive mechanism for NP delivery of 
anticancer drugs (15).
The first applications of PBPK for simulation of NPs 
distribution emerged in 2006 as a potentially valuable 
tool to inform about NP hazard, as recently indicated in 
the Organization for Economic Cooperation and Develop-
ment (OECD) guidelines (11). One of the main challenges 
in the development of PBPK modeling for NPs is accu-
rate estimation of the correlation between NPs properties 
and distribution patterns in vivo. Experimental in vitro 
approaches have recently been developed to describe the 
interaction between NPs and different cell populations, 
providing methods to better understanding distribution 
of NPs. Importantly, such data can be integrated into the 
PBPK modeling (12). Size (magnetic and hydrodynamic 
diameters), shape, superficial charge and chemical com-
position are some properties of SPIONs that can deter-
mine their uptake by macrophages, accumulation in the 
cells, penetration through capillaries as well as kidney 
ultrafiltration (15, 16).
The main aim of this study was to create a PBPK model 
able to predict the pharmacokinetics of nanostructured 
systems in mice and humans. The model was used to gain 
a better understanding of the nanotoxicological potential 
of SPIONs with neutral mPEG2000 coating. Additionally, 
a novel experimental approach was developed to estimate 
the kinetics of NPs uptake into macrophages, with subse-
quent integration into the PBPK model.
Materials and methods
Materials
The cell culture medium (RPMI and IMDM), fetal bovine serum (FBS), 
Hank’s balanced salt solution (HBBS), ficoll paque, EDTA and rea-
gents used in the ferrozine assay were purchased from Sigma-Aldrich 
(Munich, Germany). The DMEM medium was purchased from  Cultilab 
(São Paulo, Brazil) and antibiotics and HEPES were purchased from 
GIBCO (Grand Island, NY, USA). The MicroBeads, macrophage-colony 
stimulating factor (M-CFS) and columns used in the separation and 
differentiation of CD14+ monocytes to macrophages were purchased 
from Miltenyi Biotec Inc (Auburn, AL, USA). The blood buffy coats 
were obtained from regional blood transfusion center ( Liverpool, 
UK).
Superparamagnetic iron oxide nanoparticles (SPIONs)
SPIONs were provided by CNEA – Atomic Center of Bariloche, 
 Bariloche, Argentina and are composed of superparamagnetic iron 
oxide (Fe3O4) NP, coated with oleic acid and the conjugate phos-
phatidyletanolamine – methoxy polyethylene glycol with mw 2000 
(PE-mPEG2000), as illustrated in Figure S1 (Supplementary mate-
rial). The NPs were prepared by thermal decomposition of orga-
nometallic precursor iron (III) acetylacetonate (Aldrich, St. Louis, 
MO, USA) at high temperature (17, 18). NPs were coated with a bi-
layer composed of oleic acid (Sigma-Aldrich, St. Louis, MO, USA) 
and PE-mPEG2000(1,2-dioleoyl-sn-glycero-3-phosphoethanola-
mine-N-[methoxy(polyethylene glycol)-2000], ammonium salt, 18:1 
PE-PEG2000, purity >99%, Avanti Lipids, Alabaster, AL, USA). The 
ratio between nanoparticle to conjugate was 1:2 wt (1 mole of nano-
particle to 0.16 of mPEG phospholipid conjugate). Morphological and 
structural characterization of the SPIONs was made by transmission 
electron microscopy (TEM). Size and surface charge were determined 
by dynamic light scattering and laser-Doppler anemometry, using 
a Zetasizer Nano ZS (Malvern Instruments, Worcestershire, UK), 
equipped with 173° scattering angle, as previously described (19). 
In addition, Fourier transform infrared spectroscopy was performed 
to evaluate the formation of the organic bi-layer. Magnetic charac-
terization of the SPIONs was performed by magnetization curves as a 
function of an applied field at room temperature (in a vibrating sam-
ple magnetometer, VSM, Lakeshore) and temperature (SQUID mag-
netometer, MPMS6 - Quantum Designs).
Animals and treatments
We maintained 6–8 week-old Swiss albino male mice in accordance 
with the Ethics Committee for Animal Use as approved by the Animal 
Care and Use Committee (Opinion number 01/2012). The mice were 
housed at 23 ± 2°C and a relative humidity of 50–60% under a 12:12 h 
light: dark cycle with food and water given ad libitum. The weighed 
animals were divided into four groups of 10 mice each. As there are 
currently no guidelines or standard methodologies for in vivo tox-
icity, we chose to estimate doses and treatment/monitoring time 
according to the Organization for Economic Co-operation and Devel-
opment (OECD) guidelines 420 for investigating the oral toxicity of 
any new substance. The control group received only vehicle (saline) 
and the treated groups received 510, 1020, 2040 μg/mouse of SPIONs. 
The solutions were administered intravenously in a single dose. On 
the 14th day after the treatment, the animals were sacrificed follow-
ing standard procedure and the liver, spleen, lung, kidney, heart and 
brain were harvested for SPION quantification.
SPIONs quantification: The samples of each organ were processed 
through dehydration and maintained frozen until the moment of 
analysis. Specifically, liver, lung, heart, brain, spleen and kidney 
were extracted and fixed in formalin solution for 48  h and then 
through a series of ethanol solutions 70, 96, and 100% v/v succes-
sively. Subsequently, the SPIONs were quantified ex vivo, i.e. in the 
animal tissues by means of magnetization measurements, using a 
calibration curve and the superparamagnetic property of the system. 
This was conducted as previously described and SPIONs are com-
pletely distinct from the endogenous iron (20). Briefly, the magneti-
zation curve as a function of the applied field for a known amount of 
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tissue was measured in VSM and SQUID (very low magnetic signal). 
The diamagnetic component of the curve was obtained from the lin-
ear fit of the high field region (>7 kOe). The saturation magnetization 
of the magnetic (or superparamagnetic) component of the curve was 
obtained from the linear coefficient of the linear fit. By comparing 
this value with the saturation magnetization of the NPs measured 
previously, it was possible to determine the NPs concentration within 
the sample. Four values were obtained for each magnetization curve 
(from the four quadrants), and the arithmetic mean of these four 
values was used. This technique allows measurement up to 1 μg of 
SPIONs.
Experimental ex vivo/in vitro assays
Cell culture: Murine macrophage cell line (J774) was obtained from 
Banco de Células do Rio de Janeiro (BCRJ, Brazil). The cells were cul-
tured in DMEM medium supplemented with 10% heat-inactivated 
fetal bovine serum, 100 U/mL penicillin, 100 μg/mL streptomycin, 
10 mM HEPES and maintained at 37°C in a 5% CO2 humidified atmos-
phere. Every 2 days, the cells were passaged, and the medium was 
replaced.
Human PBMCs (peripheral blood mononuclear cells) were iso-
lated from buffy coats by gradient density centrifugation. An aliquot 
of buffy coats were slowly added to a Ficoll-paque reagent and cen-
trifuged (30 min, 400 × g). PBMCs were removed from the solution, 
washed with HBSS and centrifuged (5 min, 400 × g). The cell pellet 
was resuspended and cultured in RPMI 1640 media containing 10% 
FBS. After 24 h of incubation, CD14+ monocytes were isolated for gen-
eration of macrophages. For that, CD14 MicroBeads Kit (for human 
samples), from Miltenyi Biotec Inc., was used according to the manu-
facturer’s instructions.
Initially, 107 cells were washed with HBBS and resuspended in 
a buffer (HBBS, 0.5% of albumin, 2  mM EDTA) and CD14 MicroBe-
ads and refrigerated (2–8°C) for 15 min. After incubation, cells were 
washed with buffer and centrifuged for 10 min at 300 × g. The super-
natant fraction was aspirated completely and cells were resuspended 
in buffer. The CD14+ separation was performed using magnetic MACS 
separation applying the labeled cells into the magnetic columns. 
The CD14+ cells were eluted and counted and platted using IMDM 
medium supplement with 20% FBS and 100 ng/mL macrophage-col-
ony stimulating factor (M-CFS). Cells were maintained at 37°C in a 5% 
CO2 humidified atmosphere, the medium was replaced every 2 days 
and after 7 days macrophages were used to determine SPION uptake.
Quantitative human macrophage uptake of SPIONs: Primary 
macro phages (2 × 106) were incubated with crescent concentrations 
(1, 10 and 100 μg/mL) of SPIONs for 1, 6 and 24 h. After the incuba-
tion time, the uptake of SPIONs was determined using colorimetric 
ferrozine assay according to Riemer and collaborators (21) with some 
modifications. The cells were washed tree times using the buffer 
HBBS to remove all the SPIONs from the supernatant fraction and 
were detached using trypsin. The number of cells in each well was 
counted to determine the SPIONs uptake per cell. After centrifugation 
for 5 min at 400 × g cells were lysed with NaOH for 2 h on a shaker 
in a humidified atmosphere. Aliquots of cell lysates were used to 
quantify the iron content adding the iron-releasing reagent (freshly 
mixed solution of 1.4 M HCl and 4.5% w/v of KMnO4 in water) and 
HCl 10  mM. These mixtures were incubated overnight at 60°C in a 
fume hood. Once the samples reached the room temperature, the 
iron-detection reagent (6.6 mM ferrozine, 6.5 mM neocuproine, 2.5 M 
ammonium acetate, 1 M ascorbic acid dissolved in water) was added 
and after 30 min of incubation an aliquot of each sample were trans-
ferred to a 96 well plate and read in a microplate reader at 560 nm. 
The iron content of samples was determined comparing the results 
with the calibration curve constructed in parallel (FeCl3 standards, 
NaOH 50  mM, iron-releasing reagent and iron-detection reagent). 
The macrophage uptake was determined using a standard calibra-
tion curve. The results were expressed as concentration of iron/cell, 
based on the number of cells in each well.
Quantitative murine macrophage uptake of SPIONs: For mice a cell 
line was used for the SPIONS uptake evaluation since the blood vol-
ume required to isolate a sufficient number of monocytes would be 
extremely high. Murine macrophages cell line (1 × 106) was incubated 
with crescent concentrations (1, 10 and 100 μg/mL) of SPIONs for 1, 6 
and 24 h. After the incubation time, the uptake of SPIONs was deter-
mined using colorimetric ferrozine assay as previously described. 
The macrophage uptake was determined using a standard calibra-
tion curve. The results were expressed as concentration of iron/cell, 
based on the number of cells in each well.
Physiologically-based pharmacokinetic (PBPK) model
The structure of the PBPK model is summarized in Figure  1. The 
PBPK model is a mathematical representation of the molecular, 
physiological and anatomical processes defining the distribution of 
SPIONs. The organ weights of mice are presented in Table S1 (Sup-
plementary material) and were calculated as a percentage of the total 
body weight, according to previous works (22–24) and experimental 
results. The regional blood flows for mice were defined as previously 
described (23, 25–27) and are summarized in the Supplementary 
material (Table S2). Human demographics and anatomical factors 
such as height, weight, age, gender and body mass index (BMI) 
were defined as previously described (28). These values were used to 
simulate organ and tissue volume (liver, lung, kidney, heart, brain, 
spleen, adipose, intestine, muscles, testes and skin) through allomet-
ric equations.
All organs were connected with consideration of regional blood 
flow and NPs excretion was simulated through the biliary and urinary 
routes as previously described (29). The urinary excretion constant is 
described in the Supplementary Table S3 and was optimized for mice 
to best agree with the in vivo data (30). A factor was included in the 
model to calculate the biliary excretion, with variability ranging from 
70 ± 20%. For the human PBPK model the urinary excretion constant 
as well as the biliary excretion equation used for the mice model was 
applied. The urinary excretion was defined as follow:
urinary excretion NPsUrinary_excretion k B= ∗
where kurinary excretion (min−1) is the urinary constant and BNPs (μg/mL) is 
the concentration of NPs in the blood.
The distribution and accumulation of NPs in organs was simu-
lated taking into account the passive diffusion of NPs through the 
capillary endothelium and the active uptake of NPs by special-
ized macrophages in the liver, spleen and lung (30). The capillary 
endothelium characteristics of each organ were described and the 
influence of the capillary fenestrations on the NPs movement was 
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mathematically represented in the PBPK model (30). The description 
of the capillary endothelium and the penetration constants included 
in the model are described in the Supplementary Table S4. The capil-
lary organ uptake was defined by the following equation as previ-
ously described (30):
organNPs CT organ blood(k Q /V )B= ∗
where korganNPs (min−1) is the constant of penetration through the capil-
lary endothelium, BCT is a factor describing the capillary fenestration, 
Qorgan (mL/min) represents the regional blood organ flow and Vblood 
(mL) is the total blood volume.
Tissue-resident macrophages are present mainly in the liver, 
spleen and lung and have as one of their functions the capacity to 
clear pathogens, cell debris and particles, mediating the uptake and 
distribution of NPs (31, 32). Uptake of SPIONS by murine macrophage 
cell line and primary human monocyte-derived macrophages were 
quantified at different time points using a colorimetric assay as 
described above. The macrophage intrinsic clearance for liver, spleen 
and lung was derived considering the number of macrophages in 
each organ using the following equation:
int, organ int macrophages organCL CL N W= ∗ ∗
where CLint, organ (mL/min/organ) is the intrinsic clearance for each 
organ, CLint is the clearance measured in vitro (mL/min/million of 
murine macrophage cell line for mice model and primary human 
monocyte-derived macrophages for human one), Nmacrophages is the 
number of macrophages per gram of tissue: 8.6 × 105 for human liver 
(33), 1 × 107 for mouse liver (34), 2 × 106 for human spleen (35), 4.5 × 106 
for mouse spleen (36), 1.1 × 106 for human lung (23), and 3 × 107 for 
mouse lung (37). Worgan (g) is the weight of the organ in grams. Addi-
tionally, we have included a factor in the model where only a variable 
percentage of cells in the liver, spleen and lung can mediate uptake 
of SPIONs (70 ± 20%). The uptake of SPIONs is further regulated by 
the flow of blood to the organs. Consequently the total NPs uptake by 
macrophages was described by the following equation to derive the 
organ clearance from blood for each organ:
organ organ int organ intCL Q CL / Q CL( ) ( )= ∗ +
where CLorgan is organ clearance from blood, Qorgan (mL/min) is the 
regional organ blood flow and CLint (mL/min/1 × 106 cell) represents 
the intrinsic clearance for each organ.
The release rate of NPs from macrophages and capillaries for the 
mouse model were optimized to best agree with the accumulation 
described in mice. For the human model we used the same constants 
validated for the mice model. A detailed description of constants is 
described in the Supplementary material. Equations used to define 
the release of SPIONs from macrophages and capillaries are defined 
as follow:
organ_release_cap organ.NPs
organ_release_macrophage organ.NPs
Organ_release_cappilary k N
Organ_release_macrophage k N
= ∗
= ∗
where korgan_release_cap (min−1) and korgan_release_macrophage (min−1) represent the 
constant defining the NP release from capillary and macrophages; 
Norgan.NPs means the amount of NPs presented in the organ. The model 
was implemented in Matlab version 2014a using Simbiology toolbox.
Statistical analysis
The results of in vitro experiments were presented as means ± stand-
ard deviation (SD) of nine wells derived from three independent cul-
tures and compared by two-way ANOVA, followed by Bonferroni’s 
test. The results of in vivo studies were presented as mean ± SEM 
(n = 7) and data was compared by one-way ANOVA, followed by Dun-
nett’s test. *p < 0.05 was taken as statistically significant.
Results
SPIONs characterization
The SPIONs evaluated in this paper had spherical shape 
as demonstrated by TEM in the Figure S2/A. The Fe3O4 
particles presented high crystallinity and mean dia-
meter of 21  nm (σ = 0.10). The hydrodynamic diameter 
obtained for SPIONs using DLS (dynamic light scatter-
ing) was 168.9 ± 1.1  nm and is presented in the Figure 
S2/B. The SPIONs exhibited a negative surface charge of 
Figure 1: Schematic diagram of the murine and human PBPK models. The single black arrow indicates the passive diffusion of NPs through 
the capillary fenestrations; the double black arrows represent the passive diffusion plus the active uptake of NPs by macrophages. The 
dashed arrows indicate the release of NPs from the organ or tissues to the systemic circulation. The diagram also shows the biliary and 
urinary excretion of NPs.
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mice treated with 2040 μg, the highest SPIONs accumula-
tion was detected in the liver and spleen.
Murine macrophage uptake of SPIONs 
and macrophage clearance
Figure  3A shows the uptake profile of SPIONs by the 
murine macrophages after 1, 6 and 24  h of incubation. 
For mice macrophage the uptake of SPIONs was concen-
tration-dependent, with the highest uptake of SPIONs at 
100  μg/mL for all the time point evaluated. Incubation 
for 1 h resulted in an increase in SPION uptake compared 
to the 6 and 24 h incubations. The macrophage clearance 
was determined using the equation described in Materi-
als and methods and data obtained with the mean of the 
three concentrations evaluated in 6  h of treatment was 
included in the mice model.
Primary human macrophage uptake 
of SPIONs and macrophage clearance
Figure 3B shows the uptake profile of SPIONs by the mac-
rophages after 1, 6 and 24  h of incubation. The results 
suggest that human macrophage uptake of SPIONs is time- 
and concentration-dependent, with the highest uptake of 
SPIONs at 100 μg/mL. Incubation for 24 h resulted in an 
increase in SPION uptake compared to the 1 and 6 h incu-
bations. The macrophage clearance was determined using 
the equation described in Materials and methods and the 
data obtained with the mean of the three concentrations 
evaluated in 6 h of treatment was included in the human 
model.
Physiologically-based pharmacokinetic 
(PBPK) model
Murine PBPK modeling
The PBPK model generated was compared against in vivo 
results and showed to be effective in the prediction of the 
SPION distribution. The in vivo data are summarized in 
Figure 4. The simulated SPIONs distribution was in good 
agreement with the in vivo accumulation, with maximum 
difference of three-fold for the brain. The accumulation of 
SPIONs in the heart was higher in vivo compared to the 
PBPK prediction for the 510 μg dose. The simulated SPIONs 
concentrations were 1.32 μg/g of tissue vs. 13.3 μg/g in vivo. 
For the kidney, the accumulation of SPIONs was higher in 
−18.2 ± 5.18 mV (data not shown). The formation of the bi-
layer leads to an increase in the hydrodynamic diameter of 
the system which results in the difference of size from TEM 
to DLS analysis. In addition, the FT-IR spectrum of the 
SPIONs coated with mPEG2000  magnetically separated 
clearly evidences the presence of PE-mPEG2000 complex 
and oleic acid, confirming the formation of the bi-layer. 
Magnetization curves as a function of applied field (MxH) 
and temperature (MxT) are presented in the Figure S2/C 
and S2/D, respectively. MxH curve at 300 K indicates a sat-
uration magnetization of MS = 72 emu/g and the curve pre-
sents non-hysteresis as expected for superparamagnetic 
behavior. Moreover, the MxT curve confirms the superpar-
amagnetic behavior of the samples at room temperature 
with mean blocking temperature around 170 K (see inset 
of Figure S2/D), in addition, it clearly shows the Verwey 
transition at TV ~ 110 K, confirming the formation of Fe3O4.
Tissue distribution in vivo
Following intravenous administration, the SPIONs were 
detectable in the spleen, liver, heart, lung, brain and 
kidney. The SPIONs could be quantified in all organs 
with the exception of the kidney of mice treated with the 
medium dose. The concentration of SPIONs in each organ 
is summarized in Figure 2. The concentration accumulated 
in organs was determined through the intrinsic magnet-
ism of SPIONs. A significant accumulation of SPIONs was 
observed in the liver, spleen, heart and lung of the mice 
treated with 510 μg of SPIONs. For the group of animals 
that received a dose of 1020 μg, a higher NP accumulation 
was seen in the spleen, liver and lung. Considering the 
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mined by magnetization. *p ≤ 0.05, **p ≤ 0.01 and ***p < 0.001 
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the model compared with experimental data for the doses 
of 1020 and 2040 μg. The SPIONs concentration in vivo 
was 0.15 μg/g vs. 1.24 μg/g and 0.28 μg/g vs. 2.27 μg/g in 
the model, respectively.
Simulated concentrations were compared with 
observed SPIONs concentrations in mice taking into 
account the three doses. Organ concentrations have been 
normalized by the dose (organ concentrations/admin-
istered dose) and expressed as ng/g tissue/μg dose. As 
represented in Figure  5, mean simulated vs. observed 
SPION concentrations (ng/g tissue/μg dose) were equal to 
11.40 vs. 18.67 (ratio = 1.63) in the spleen, 12.30 vs. 13.28 
(ratio = 1.07) in the liver, 2.66 vs. 12.43 (ratio = 4.66) in the 
heart, 7.57 vs. 11.41 (ratio = 1.50) in the lung, 2.15 vs. 1.20 
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Figure 4: Simulated and in vivo data accumulation of SPIONs in mice. The dose simulated and administered in mice was (A) 510, (B) 1020 
and (C) 2040 μg/mouse and the results are expressed as microgram of SPIONs per gram of tissue. The equivalent concentration of SPIONs 
was applied in the model. Data for skin, muscles, intestine, blood adipose and testes were not available in mice.
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by high concentrations in the spleen, liver and skin, with 
accumulation of 5.59 mg in the spleen, 1.16 mg in the liver 
and 0.69 mg in the skin.
Discussion
The aim of this study was to develop a PBPK model to 
predict the distribution and accumulation of NPs in 
vivo. Novel in vitro experimental data describing uptake 
of SPIONs in murine macrophage cell line and primary 
human monocyte-derived macrophages were integrated 
into this computational approach. NP penetration into 
tissues was modeled considering the diffusion of NPs 
through the capillary fenestration and the phagocytic 
activity mediated by macrophages (38).
Although several studies have identified SPIONs as a 
promising technology platform for various applications, 
there is a limited understanding of the pharmacokinet-
ics and this represents a major obstacle for their transla-
tion. In this scenario, the construction of predictive PBPK 
models for humans can effectively contribute (i) to devel-
opment of new tools that combine in vitro and ex vivo data 
providing a better understanding of NPs distribution in 
vivo; (ii) to the creation of a theoretical approach to risk 
assessment for NPs that reduces reliance on the use of 
animals; (iii) to accelerate studies to understand the cor-
relation between NPs physical properties and distribution 
that can inform design of future nanomaterials.
Several properties such as size, surface chemistry 
and shape can influence the interactions between NPs 
and plasma proteins, cellular uptake and toxicity (39, 40). 
The biodistribution and pharmacokinetics of inorganic 
NPs has been investigated across different technology 
platforms. Three different surface-modified 45  nm silica 
NPs showed different half-life (t½) in vivo. PEG-coated 
silica NP (PEG-SiNP) remained in the circulation longer 
(t½ = 180 min) than hydroxyl-coated silica NPs (OH-SiNP, 
t½ = 80 min) and carboxyl-coated silica NPs (COOH-SiNP, 
t½ = 35 min). Both OH-SiNP and COOH-SiNP accumulated 
in the liver 3  h after administration, while no signal of 
PEG-SiNP was detected in hepatic tissues up to 24 h (41). 
Similarly, gold-dendrimers of 5  nm with negative and 
neutral surface charge were described to accumulate 
mainly in the liver and spleen whereas positively-charged 
dendrimers showed accumulation predominantly in the 
kidney and blood (42). The impact of size on the distribu-
tion and elimination of PEG-coated gold NPs (PEG-AuNP) 
was investigated by Cho et al. (43) using small (4 or 13 nm) 
and large (100 nm) NPs. The concentrations of small NPs 
(ratio = 1.78) in the brain and 1.15 vs. 0.73 (ratio = 1.56) in 
the kidney.
Human PBPK model
The simulated pharmacokinetics of SPIONs is summarized 
in Figure 6. The distribution of SPIONs was characterized 
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remained high for 24 h in the blood whereas large NPs had 
faster clearance and elimination in 24 h. These results are 
in accordance with previous studies, in which NPs with 
diameter below 10  nm were characterized by prolonged 
circulation time (44). Therefore, size and surface chemis-
try clearly influence pharmacokinetics and distribution.
The simulated pharmacokinetics of SPIONs in the 
mouse PBPK model presented here was in good accord-
ance with the in vivo experimental data, with higher accu-
mulation predicted in the spleen, lung and liver. Higher 
accumulation in the spleen, liver and lungs can be influ-
enced by the protein corona that forms on the surface of 
NPs that mediates the interaction with cells and tissues 
and can enhance the uptake and accumulation of NPs in 
cells (45, 46). Therefore, the predicted distribution pattern 
is in accordance with previously published data describ-
ing higher accumulation in macrophage-rich organs such 
as spleen, liver and lung (47–50).
Murine macrophage cell line was used to determine 
the uptake of SPIONs as a surrogate for the RES system 
in vivo in mice. As the simulated tissue accumulation is 
in accordance with the in vivo experimental data in mice, 
the in vitro and in silico approaches were used to predict 
SPIONs distribution in humans. The PBPK model was 
used to provide a physiological and anatomical descrip-
tion of the mechanisms regulating NPs distribution in 
humans, integrating the quantification of SPIONs appar-
ent uptake in human primary macrophages for the pre-
diction of RES clearance in liver, spleen and lungs. This 
has the potential of representing a valuable tool to bridge 
investigation of NPs pharmacokinetics from pre-clinical 
species to humans, generating data across a wider range 
of materials with a better understanding of how NPs prop-
erties such as size, shape or even the possibility of protein 
corona formation can influence their distribution.
In mice, the main difference between the experimen-
tal and modeled data was found in kidney, in which the 
experimental accumulation is lower. Although our pre-
diction were overall correct, there is a fundamental lack 
of understanding related to the mechanism involved in 
accumulation of SPIONs in certain tissues. Consequently, 
additional experimental investigations including other 
population of cell to further elucidate the mechanisms 
regulating SPIONs penetration in tissues are warranted. 
An additional limitation could be represented by poten-
tial ADME differences among species used in preclinical 
studies, where accumulation of SPIONs or other nano-
materials in specific organs might be substantially differ-
ent and influenced by nanoparticle’s properties (i.e. size, 
charge and chemical structure) as well as experimental 
conditions (51).
The accumulated NPs in cells or tissues can become 
toxic or disrupt normal cell chemistry, resulting in harmful 
side effects, as already described for many authors (43, 
52–55). Therefore, the identification of NPs properties 
influencing distribution and accumulation is essential 
and may support the rational selection of technology plat-
forms for specific biomedical applications. As there is no 
data available in the literature regarding the distribution 
and accumulation of several types of NPs in human, the 
theoretical approach to risk assessment may constitute a 
valuable approach.
The distribution of NPs in humans and animals 
is mediated by numerous physiological processes in 
several tissues and organs which substantially differ 
from the pharmacokinetics of traditional formulations. 
Consequently, the generation of PBPK models for NPs 
is challenging, due to incomplete understanding of the 
molecular mechanisms defining NPs distribution as well 
as a limited availability of experimental approaches to 
inform computational models. In this work, the results 
obtained from the human PBPK model described a similar 
distribution found in the murine PBPK, with a higher NPs 
accumulation in spleen and lung. As expected, the accu-
mulation increased with higher NPs dose. These data 
should be interpreted in the context that many of the 
input data were the same for both models and the mouse 
model accurately predicted accumulation in five out of six 
tissues (considering a ≈0.5–2 fold cut-off). With the dis-
covery of novel, as well as a better characterization of the 
known mechanisms mediating SPIONs pharmacokinetics 
as more advanced in vitro assays and PBPK models are 
developed, the precision and accuracy of this computa-
tional approach is likely to increase.
Conclusions
In conclusion, the PBPK model developed showed accu-
racy in predicting the SPIONs accumulation in mice, espe-
cially in the liver, spleen and lung, when compared with 
experimental results. The results obtained from the human 
PBPK model described a similar distribution found in the 
murine PBPK, with a higher NPs accumulation in spleen 
and liver. Also, the in vitro approach using mice and 
human macrophages as an alternative to surrogate the RES 
in vivo, showed appropriate for the SPIONs accumulation 
prediction, since the similarity of obtained results.
The application of modeling techniques may have 
value in bridging between pre-clinical and human NPs 
pharmacokinetics. The integration of in vitro assays for 
ADME processes can improve PBPK approaches, allowing 
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clarification of how NPs properties influence distribution 
patterns. Consequently, although there are current gaps 
in knowledge, PBPK models have the potential to support 
the design of NPs by providing a rational approach for 
the selection of materials to build up new nanostructured 
systems with optimal pharmacological properties, as well 
as, biocompatibility.
The development of this model can support the idea 
of using a theoretical approach to surrogate the pharma-
cokinetic of nanoparticles, using in vitro uptake assays to 
take into account the nanoparticle properties and physic-
ochemical characteristics. Since the uptake study is used, 
other nanoparticles can be included in the model, avoiding 
or minimizing the use of animals. This model represents 
an initial platform to provide computational prediction 
of nanoparticle distribution and aims to promote future 
expansions of this approach, where additional variants 
such as other cell populations or nanoparticle types can 
be included.
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